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Abstract
Background: Discoveries that microglia-mediated neuroinflammation is involved in the pathological process of
depression provided a new strategy for novel antidepressant therapy. Peroxisome proliferator-activated receptor γ
(PPARγ) is a nuclear receptor regulating inflammation and microglial polarization and, therefore, a potential target
for resolving depressive disorders. Our hypothesis was that antidepressant effects could be achieved through anti-
inflammatory and neuroprotective activities by PPARγ-dependent microglia-modulating agents.
Methods: Chronic mild stress (CMS) treatment was performed on C57BL/6 mice for 6 weeks. After 3 weeks with the
CMS procedure, depressive-like behaviors were evaluated by sucrose preference (SP), tail suspension test (TST), forced
swimming test (FST), and locomotor activity. Pioglitazone was administered intragastrically once per day for 3 weeks at
different doses. Neuroinflammatory cytokines were determined by real time-PCR (RT-PCR), enzyme-linked immunosorbent
assay (ELISA), and western blot. The activated microglial state was confirmed by immunohistochemistry. N9 microglial
cells were subjected to lipopolysaccharide, pioglitazone, and GW9662 to discuss the phenotype of activated microglia by
RT-PCR, ELISA, and western blot.
Results: It was demonstrated that the PPARγ agonist pioglitazone (2.5 mg/kg) ameliorated depression-like behaviors in
CMS-treated mice, as indicated by body weight (BW), the SP test, the FST, and the TST. The amelioration of the depression
was blocked by the PPARγ antagonist GW9662. The expression of M1 markers (IL-1β, IL-6, TNFα, iNOS, and CCL2) increased,
and the gene expression of M2 markers (Ym1, Arg1, IL-4, IL-10, and TGFβ) decreased in the hippocampus of the stress-
treated mice. Pioglitazone significantly inhibited the increased numbers and morphological alterations of
microglia in the hippocampus, reduced the elevated expression of microglial M1 markers, and increased the
downgraded expression of microglial M2 markers in C57BL/6 mice exposed to CMS. In an in vitro experiment,
pioglitazone reversed the imbalance of M1 and M2 inflammatory cytokines, which is correlated with the
inhibition of nuclear factor kB activation and is expressed in LPS-stimulated N9 microglial cells.
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Conclusions: We showed that pioglitazone administration induce the neuroprotective phenotype of microglia
and ameliorate depression-like behaviors in CMS-treated C57BL/6 mice. These data suggested that the microglia-
modulating agent pioglitazone present a beneficial choice for depression.
Keywords: Pioglitazone, PPARγ, Antidepressant, CMS, Microglia, Alternative activation, Cytokine
Background
Major depressive disorder (MDD) is one of the most
frequently occurring mental disorders and has a consid-
erable rate of mortality [1]. The medications currently
available to treat depression, including monoamine
oxidase inhibitors (MAOIs), selective serotonin reuptake
inhibitors (SSRIs), and tricyclic antidepressants, are
predicated on the monoamine hypothesis. Clinical evi-
dence shows that these medications produce adequate
remission of depressive symptoms in only two thirds of
patients [2]. Moreover, monoamine antidepressants such
as SSRIs or MAOIs often have a slow onset of action
and serious side effects [3]. Increasing evidence indicates
that depression is accompanied by inflammatory re-
sponses [4, 5]. A recent study reported that the imbal-
ance of pro- and anti-inflammatory cytokines plays a
critical role in chronic mild stress (CMS)-induced
depression [6]. Research into the role of neuroinflamma-
tory responses has brought new insights into the poten-
tial etiologies of MDD and provided new strategies for
novel antidepressant therapies.
Microglia are resident innate immune cells within the
central nervous system (CNS) and play a central role in
the neuroinflammatory response. Microglia populate the
CNS during early fetal life and are present in a resting
state in the healthy brain but readily become activated in
response to brain trauma, injury, and infection [7, 8]. In
clinical research, microglial activation has also been ob-
served in patients with depression who have committed
suicide [9]. Microglial activation is often categorized into
classical (M1) and alternative (M2). M1 microglia may
contribute to dysfunction of the neurotrophic system by
expressing pro-inflammatory cytokines, such as tumor
necrosis factor-α (TNFα), IL-1β, IL-6, iNOS, and CCL2
[10]. In the M1 phenotype of microglia, the activation of
nuclear factor kB (NF-kB) may play a critical role in the
production of proinflammatory cytokines, leading to
neurotoxic outcomes [11]. The M2 phenotype, some-
times called the neuroprotective microglial phenotype,
releases different mediators including Ym1, arignase1
(Arg1), IL-4, IL-10, and TGFβ [10] to antagonize
inflammation-induced damage in the CNS [12, 13].
Stress triggers neuroinflammatory processes in several
brain regions including the frontal cortex, hypothalamus,
and hippocampus [14, 15]. More specifically, the hippo-
campus is an area particularly sensitive to chronic stress,
which was associated with evidence of inflammation
characterized by microglial activation [16]. In this study,
the hippocampus was chosen for investigation because
of the effects of hippocampal microglial activation on
stress-induced behaviors.
Pioglitazone is a highly selective agonist for PPARγ,
which causes the transcription of several genes involved
in glucose and lipid metabolism as well as with the pro-
duction of inflammatory mediators [17, 18]. In recent
years, researchers have found that PPARγ agonists might
be useful in a number of central nervous system diseases
that have a microglia-induced anti-inflammatory re-
sponse [19, 20]. Pioglitazone is primarily used as an anti-
diabetic drug [21] and recently has been used in clinical
trials for psychiatric and neurodegenerative diseases. It
has been reported that pioglitazone promotes cognitive
and functional improvements in schizophrenia and autism
[22]. Pioglitazone is also being tested in Alzheimer’s dis-
ease [23], Parkinson’s disease [24], multiple sclerosis [25],
and stroke [26]. In clinical trials, pioglitazone worked as
an adjuvant treatment for depression in insulin-resistant
subjects and was associated with improvement in glucose
metabolism [27]. Researchers have also reported that
pioglitazone had antidepressant-like effects in an acute
animal model of depression, although the mechanisms
underlying their beneficial effect remain largely un-
known [28, 29]. Accumulating evidence indicates that
inhibition of the microglia-mediated inflammatory
response is an important strategy for the treatment of
mood disease [30].
Based on the effects of PPARγ on the anti-inflammatory
response, in this study we evaluated the antidepressant-
like effects of the PPARγ agonist pioglitazone in CMS-
induced depression using a mouse model and analyzed




Male C57BL/6 mice weighing 18–22 g were purchased
from the Institute of Experimental Animals (Chengdu,
China). The animals were housed individually under
controlled conditions (23–25 °C, humidity 50–60 %, on a
12-h light/dark cycle with lights on at 8:00 a.m. and water
and food available ad libitum) and acclimatized for at least
1 week before they were used for the experiments. All the
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behavioral experiments were conducted in isolated behav-
ioral testing rooms and performed by an experimenter
who was blind to the identity of the experimental groups.
CMS procedure
The CMS procedure was performed according to previ-
ously described methods, but with small modifications
[31, 32]. The stress method followed a random schedule
of commonly used mild stressors, such as food
deprivation for 24 h, water deprivation for 24 h, cage
tilting (45°) for 24 h, damp bedding for 24 h, strobo-
scopic illumination for 24 h, overnight illumination, and
restraint stress for 2 h. The mice received one stressor
once per day with the same stressor never applied in
two consecutive days. The stress regimen lasted for six
consecutive weeks. The control group was housed in a
separate room and had no contact with the stressed ani-
mals. After the 3 weeks with the CMS procedure, the
stress-treated mice were divided into a vehicle group
and drug-treatment groups. The body weight (BW) and
sucrose preference (SP) data during the first 3 weeks
while the mice were being stressed showed no statistical
differences between the mice. The additional files
showed this in more details (see Additional file 1 and
Additional file 2).
Drug treatment
Depressive-like behaviors appeared after the 3 weeks of
CMS induction. At the end of the 3-week induction
period, the drugs and vehicle were administered intra-
gastrically once per day for an additional 3 weeks. In
order to determine the optimal dosage, for experiment
1, the mice were allocated into six experimental groups
according to treatment: Control (control group not sub-
mitted to CMS, n = 26), CMS + Vehicle (CMS group
without pioglitazone, n = 26), CMS + 2.5 mg/kg (CMS
animals and administered with pioglitazone at 2.5 mg/
kg, n = 26), CMS + 5 mg/kg (CMS animals and adminis-
tered with pioglitazone at 5 mg/kg, n = 26), CMS +
10 mg/kg (CMS animals and administered with pioglita-
zone at 10 mg/kg, n = 26), CMS + 20 mg/kg (CMS animals
and administered with pioglitazone at 20 mg/kg, n = 26).
In experiment 1, BW and SP test were evaluated in the
same group (n = 10). The tail suspension test (TST) and
locomotor activity were assessed in the same animals
(n = 8). The forced swimming test (FST) was estimated
in the six groups (n = 8). In all the experiments, the
vehicle was 10 % dimethyl sulfoxide diluted with 0.9 %
saline.
In order to investigate the possible involvement of a
PPARγ pathway, for experiment 2, the mice were
allocated into five experimental groups according to
treatment: control (control group not submitted to
CMS, n = 26), CMS + Vehicle (CMS group and 0.9 %
saline, n = 26), CMS + Piog (CMS animals and adminis-
tered with pioglitazone at 2.5 mg/kg, n = 26), CMS +
GW (CMS animals and administered with GW, the mice
were pretreated for 1 h with 1 mg/kg of GW, a spe-
cific PPARγ inhibitor, before pioglitazone administra-
tion, n = 26), CMS + Piog + GW (CMS animals and
administered with pioglitazone at 2.5 mg/kg and GW
at 1 mg/kg, n = 26). In experiment 2, BW and SP test
were evaluated in the same animals (n = 10). The TST
and locomotor activity were assessed in the same
mice (n = 8). The FST was estimated in the five group of
animals (n = 8). The immunofluorescence experiment was
performed for microglial phenotype in the control (n = 5),
CMS + Vehicle (n = 5), CMS + Piog (n = 5), CMS + GW
(n = 5), and CMS + Piog + GW (n = 5) animals. The
relative expression of the M1 and M2 markers was
quantified by real time-PCR (RT-PCR) in all of the
five groups (n = 5 for each group). The pioglitazone
(Sigma, USA) and GW9662 (Sigma, USA) were all di-
luted with 10 % dimethyl sulfoxide (Sigma, USA) in
0.9 % saline. Thirty minutes after the last drug ad-
ministration, the mice were used in the behavioral
tests as well as in cellular and molecular experiments.
Body weight measurement and sucrose preference test
As the primary assessment indicators for BW and anhe-
donia in an animal model of depression, BW and SP
were measured at the onset of the CMS schedule and
every week until the end of the 6-week CMS test. BW
was measured once a week at 5:00 p.m. on Mondays to
calculate the BW gain during the CMS period. The BW
test and the SP test were administered to all the mice in
all the groups.
Before the SP test, individually housed mice were
habituated to consume 1 % sucrose solution. The test
involved 20 h of food and water deprivation, followed by
1 % sucrose and water intake for 2 h. The position of
the two bottles (left/right sides of the cages) was varied
randomly in each trial. The intake of sucrose solution
and water was recorded every week at 5:00 p.m. on
Tuesdays for 6 weeks throughout the CMS experiment
to evaluate the anhedonia of the mice. The SP was
calculated according to the ratio: SP = sucrose intake (g)/
[sucrose intake (g) + water intake (g)].
Locomotor activity measurement
To measure the locomotor activities of the mice, we
used a 36-point infrared ray passive sensor system
(model No. ZZ-6, Taimeng Tech Ltd. Chengdu, China)
in the sixth week of the experimental procedure, that is,
at the end of the test. Each of the mice was placed in a
chamber of an autonomous movement device to accom-
modate to the environment for 1 min before the test.
The total locomotor activity (standing and movement)
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of the mice was automatically recorded by the autono-
mous movement equipment for 10 min.
Tail suspension test
The TST is based on the fact that mice subjected to the
short-term, inescapable stress of being suspended by
their tail will develop an immobile posture [33]. In this
test, which was also done once to all mice in the sixth
week of the experiment, adhesive tape (approximately
1 cm from the tip of each mouse’s tail) was used to sus-
pend the mice by the tail from a ledge 20 cm above a
tabletop. Each animal was isolated to avoid interference
during the experiment. The mice were recorded by a
video camera. Immobility was defined as the absence of
movement for 6 min and was used as an evidence of
hopelessness.
Forced swimming test
The FST models depressant-like behavior as decreased
immobility. We used the method described by Porsolt
[34] with a slight modification. The mice were placed in
an open glass cylindrical container (20 cm in height and
14 cm in diameter) with 10-cm-deep water (25 ± 1 °C)
for 6 min. Immobility time was recorded as the amount
of time the mice floated passively without struggling in
the water. This test was also done once to all mice in
the sixth week of the experiment. The duration of
immobility in the last 4 min of the total 6 min was
recorded as evidence of despair.
Immunofluorescence
The animals were anesthetized with pentobarbital
sodium, perfused transcardially with pH 7.2 phosphate-
buffered saline (PBS) and 4 % paraformaldehyde.
Coronal sections were cut into 35-μm slices with a
sliding vibratome (CM1900; Leica Microsystems,
Wetzlar, Germany). The immunofluorescence and statis-
tical methods were based on our previously described
methods [35]. The brain sections that contained the
hippocampus and N9 microglial cells were permeabilized
with 0.5 % Triton X-100 for 10 min. The samples were
placed in 10 % donkey serum for 2 h; incubated with a pri-
mary antibody, goat anti-ionized calcium-binding adaptor
protein-1 (Iba1) (1:600; Abcam), overnight at 4 °C; and
then incubated with a fluorescent-dye-conjugated second-
ary antibody, DyLight 549-conjugate donkey anti-goat
(1:500; Jackson ImmunoResearch). Positive cells were
manually counted under a ×40 objective microscope
(Olympus BX51). The photomicrographs were saved as
TIF files and quantitatively analyzed using the cell counter
in the ImageJ software (version 1.45J; National Institutes
of Health, Bethesda, MD, USA).
Cell culture
Murine N9 microglial cells (kindly provided by Dr. H.
Han, Institute of Neuroscience, Fourth Military Medical
University, China) were cultured in DMEM (Invitrogen,
USA) with the addition of 10 % fetal bovine serum
(Invitrogen, USA), 100 U/ml penicillin (Invitrogen,
USA), and 0.1 mg/ml streptomycin (Invitrogen, USA) in
a humidified atmosphere of 5 % CO2 and 95 % air at
37 °C. The cells were passaged two to three times per
week and then distributed into 24-well plates at a dens-
ity of 5 × 105 cells per well. The cultivated N9 cells were
treated with or without lipopolysaccharide (LPS) (for
simulating an organism’s inflammatory environment in
vitro), pioglitazone, and GW9662. The concentrations
were as follows: LPS (Sigma, USA): 100 ng/ml; pioglita-
zone (Sigma, USA): 10 μmol, and GW9662 (Sigma,
USA): 1 μmol. After culturing for 24 h, the cells were
used in RT-PCR, ELISA, and western blot detection.
ELISA
The N9 cells were treated with RIPA Lysis Buffer (Beyo-
time Institute of Biotechnology, China) and centrifuged
at 12,000 rpm for 5 min. The supernatants were col-
lected to detect the protein levels by ELISA and western
blot. The expression of IL-1β and TNFα was assayed
using ELISA kits (NeoBioscience Technology Co., Ltd.,
China) according to the manufacturer’s protocol. The
detection limits for IL-1β and TNFα were 1 pg/ml. The
absorbance at 450 nm was recorded using a microplate
reader.
Western blot analysis
The protein concentrations were determined with a
BCA kit (Beyotime Institute of Biotechnology, China)
following the manufacturer’s guidelines. Equal amounts
of protein were separated by SDS-polyacrylamide gel
electrophoresis, transferred to polyvinylidene difluoride
membranes (Millipore, USA), and blocked with 5 % skim
milk incubated with primary antibody either overnight
at 4 °C or for 1 h at room temperature. The membranes
were washed and incubated with anti-rabbit IgG horse-
radish peroxidase-conjugated secondary antibody (1:500;
Beyotime Institute of Biotechnology, China) using ECL-
Plus kits (Millipore, USA) as a detection system. Densi-
tometry was performed to quantify the signal intensity
using ImageJ software (Version 1.45 J; National Institutes
of Health, Bethesda, MD, USA). The primary antibodies
were rabbit anti-Ym1 (1:800; Abcam, USA), rabbit anti-
Arg1 (1:800; Abcam, USA), and rabbit anti-IkBα (1:1000;
Cell Signaling Technology, USA).
Real-time PCR
The mice were sacrificed by decapitation, and the hippo-
campus was quickly dissected out and placed in sterile
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tubes. The total RNA of the hippocampus and the N9
cells were harvested using Trizol reagent (Invitrogen,
USA) according to the manufacturer’s instructions. The
first strand complementary DNA (cDNA) was synthe-
sized with a cDNA Synthesis Kit (TAKARA, Japan). The
PCR amplifications were conducted in a 10-μl reaction
volume. RT-PCR was carried out in a Bio-Rad CFX 96 at
95 °C for 10 min followed by 38 cycles of 95 °C for 3 s,
60 °C for 30 s, and 72 °C for 5 s. The relative gene ex-
pression was calculated using the Ct method, as in our
previous study [12]; the loading control was β-actin.
Primer sequences were as follows: IL-1β, 5′-CCAGC
AGGTTATCATCATCATCC-3′, 5′-CTCGCAGCAGCA
CATCAAC-3’, [GenBank: NM_008361.4]; IL-6, 5′-
AGAGATACAAAGAAATGATGGA-3′, 5′-AGCTATG
GTACTCCACAAGACCA-3′, [GenBank: NM_03116




Bank: NM_010927.4]; CCL-2, 5′-CTGATGCAGGTC
CCTATGGT-3′, 5′-GCAGGATTTTGAGGTCCAGA-
3′, [GenBank: NM_009137.2]; Ym1, 5′-TCACTTACAC
ACATGAGCAAGAC-3′, 5′-CGGTTCTGAGGAGTAG
AGACCA-3′, [GenBank: NM_009892.3]; Arg1, 5′-GG
AAGACAGCAGAGGAGGTG-3′, 5′-TATGGTTACCC











The data were expressed as means ± SEM. The results of
the BW and SP test were analyzed with a two-way ana-
lysis of variance (ANOVA). The other statistical signifi-
cances were assessed by one-way ANOVAs followed by
Bonferroni’s multiple comparison test using Windows®
v.17 (SPSS Inc., Chicago, USA). A value of p < 0.05 was
considered statistically significant.
Results
The effects of different doses of pioglitazone on CMS-
treated mice
The experimental design is presented in Fig. 1a. There
were no differences in the BW or SP between the six
groups at the baseline measurement (week 0: p > 0.05,
respectively). The BW of the CMS mice slowly increased
compared with that of the control group throughout the
3 weeks of the CMS procedure. After 3 weeks of con-
tinuous treatment with pioglitazone for the CMS mice,
the doses of 2.5 and 5.0 mg/kg pioglitazone had restored
the CMS-induced BW reduction in the mice to a level
comparable to that of the CMS + Vehicle group (p < 0.01
and p < 0.05, respectively; Fig. 1b, c). A reduction in the
relative sucrose intake (anhedonia) was observed in the
mice after the 3-week period of CMS. The anhedonia
improved following the 2.5 and 5.0 mg/kg dosages to a
level that was comparable to that of the CMS + Vehicle
mice (p < 0.01, both; Fig. 1d, e). Additional file 1 pro-
vides the 6-week details of BW and SP in experiment 1.
With 6 weeks of CMS induction, the immobility time
increased in the CMS + Vehicle mice. Three weeks of
treatment with pioglitazone at 2.5, 5.0, and 10 mg/kg
significantly reduced the duration of immobility com-
pared to the untreated CMS group (p < 0.01; Fig. 1f ).
In the TST, after 6 weeks of CMS induction, the dur-
ation of the immobility increased in the CMS group
compared with the control group. The immobility time
of the pioglitazone (2.5 and 5.0 mg/kg)-treated mice was
shorter than that of the CMS + Vehicle mice (p < 0.05;
Fig. 1g).
As shown in Fig. 1h, the CMS + Vehicle group showed
decreased spontaneous movement times compared with
the control animals (p < 0.05; Fig. 1h). The spontaneous
activity levels increased in the 2.5, 5.0, and 10 mg/kg
pioglitazone groups compared with the stressed, but
untreated, mice. According to the depression indicators
above, the antidepressant effect was greatest at the
2.5 mg/kg pioglitazone level.
The effects of pioglitazone on behaviors of CMS-treated
mice blocked by GW9662
As shown in Fig. 2a, GW9662 was chosen to inhibit the
PPARγ activity. The BW and SP baselines did not differ
between the five groups (p > 0.05, both; Fig. 2b, d), but
the CMS induction reduced the BW and SP in week 6
compared with the control group. After 3 weeks of drug
administration, pioglitazone reversed the body loss and
increased the sucrose intake compared with the CMS +
Vehicle mice. GW9662 aggravated the weight loss and
anhedonia after the CMS procedure (p < 0.01, p < 0.05;
Fig. 2c, e). Mice treated with pioglitazone and GW9662
in the CMS groups also decreased in BW, but not SP,
compared to the CMS + Vehicle group. Only the week 6
data for the BW and SP tests are shown in Fig. 2.
Additional file 2 shows more details for the BW and SP.
The mice exposed to CMS induction showed reduced
locomotor movement during the 6 weeks of stress treat-
ment compared with the control animals. Pioglitazone
increased the durations of their spontaneous movement
after 3 weeks of administration, whereas GW9662 treat-
ment decreased the spontaneous activity level compared
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Fig. 1 (See legend on next page.)
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with the controls and the CMS + Piog (p < 0.05). Pioglit-
azone and GW9662 combined did not significantly
change the effect of the CMS (Fig. 2f ).
In the FST, the duration of the immobility increased in
the CMS + Vehicle animals, whereas the time was re-
stored to the control level with a 3-week pioglitazone
treatment. After administration with the PPARγ antag-
onist GW9662, the immobility time increased, compared
to the control mice (p < 0.05; Fig. 2g). There were no sig-
nificant differences in the FST between the treatment of
the CMS-exposed mice with the two-drug (pioglitazone
and GW9662) combination and the control group.
Figure 2h depicts the effect of PPARγ on depression
improvement in the TST experiment. The immobility
time of the CMS + Vehicle as well as of the CMS +
GW9662 mice was longer than that of the control
group. Mice that received pioglitazone either alone or in
combination with GW9662 had a shorter immobility
duration than the CMS + Vehicle mice (p < 0.05; Fig. 2h).
The activity of PPARγ affects the microglial activated
status
After 6 weeks of CMS induction, the morphology of the
Iba1+ microglia was amoeboid (Fig. 3a) and their num-
bers increased in the hippocampus of the CMS + Vehicle
mice compared with the control animals (Fig. 3b). The
number of Iba1+ microglia in the mice which received
the CMS induction was lower in the animals that re-
ceived the PPARγ agonist, pioglitazone. The number of
Iba1+ microglia increased and their amoeboid shape
remained following the administration of the PPARγ an-
tagonist GW9662. Pioglitazone and GW9662 treatment
together did not change the number or morphology of
the Iba1+ microglia compared with the CMS + Vehicle
group (p < 0.01; Fig. 3b).
We next studied the activated phenotype of the micro-
glia in the hippocampus. The expression of M1 markers,
IL-1β, IL-6, TNFα, iNOS, and CCL2, increased in the
CMS + Vehicle mice. After treatment with pioglitazone,
the expression of M1 markers decreased. Administration
of pioglitazone and GW9662 did not change the
activation status of the microglia in the CMS animals
(Fig. 4a: p = 0.018; Fig. 4b: p = 0.051; Fig. 4c: p = 0.045;
Fig. 4d: p = 0.008; Fig. 4e: p = 0.032). In the M2 status,
the messenger RNA (mRNA) expression (Ym1, Arg1,
IL-4, IL-10, and TGFβ) was lower following the 6-week
CMS procedure. The decreases were attenuated by
administration with pioglitazone (Fig. 5a: p = 0.001;
Fig. 5b: p = 0.004; Fig. 5c: p = 0.001; Fig. 5d: p = 0.037;
Fig. 5e: p = 0.046).
The effects of pioglitazone on LPS-stimulated N9
microglial phenotypes in vitro
In order to confirm the effect of pioglitazone on the
microglial phenotypes, we detected the microglial activa-
tion status by using LPS simulate an organism’s inflam-
matory environment in an N9 microglial line. As shown
in Fig. 6, the expression of the M1 phenotype (IL-1β, IL-
6, TNFα, iNOS, and CCL2) increased significantly after
the LPS treatment compared with the control, Con +
Piog, and Con + GW microglial cells. Pioglitazone mark-
edly blocked the upregulation of these markers in the
LPS groups. Co-treatment with pioglitazone, GW9662,
and LPS showed no difference in the LPS microglia
(Fig. 6a: p = 0.025; Fig. 6b: p = 0.023; Fig. 6c: p = 0.001;
Fig. 6d: p = 0.001; Fig. 6e: p = 0.036). In contrast, the ex-
pression of the M2 markers, Ym1, Arg1, IL-4, IL-10, and
TGFβ, decreased after LPS stimulation, but these
expressions improved after treatment with pioglitazone.
The microglial activated phenotypes of the LPS + Piog
+ GW group were similar to the LPS microglia
(Fig. 7a: p = 0.010; Fig. 7b: p = 0.012; Fig. 7c: p = 0.025;
Fig. 7d: p = 0.040; Fig. 7e: p = 0.032). Consistent with
these mRNA expressions, protein expression of the
M1 pro-inflammatory cytokines (IL-1β and TNFα)
was also upregulated by LPS, and these effects were
significantly inhibited by pioglitazone. There were no
differences between the LPS and the LPS + Piog + GW
cells (Fig. 6f: p < 0.001; Fig. 6g: p < 0.001). The protein
levels of the M2 anti-inflammatory mediators (Ym1
and Arg1) were also reduced with LPS treatment, and
these decreases were attenuated by treatment with pi-
oglitazone. There was no difference between the LPS
and the LPS + Piog + GW microglia in their protein
expression of either Ym1 or Arg1 (Fig. 7g: p = 0.041;
Fig. 7i: p = 0.026). The results for the M1 and M2
markers in the N9 microglia cells in vitro were con-
sistent with the consequences in the mice in vivo.
Next, we investigated whether pioglitazone exerted
its anti-inflammatory effects through regulating NF-
kB activity. Following the LPS treatment, the level of
IkBα in the N9 microglia dropped compared with all
(See figure on previous page.)
Fig. 1 Effects of pioglitazone at different doses on CMS mice. a Schematic diagram of the experimental design. BW was measured every week
(b). The 2.5 mg/kg dose showed the best result in recovering the BW in the CMS mice (c, n = 10). Anhedonia was detected by SP over the course
of the 6-week-long experiment (d, e, n = 10). The duration of immobility in the FST (f) and TST (g) increased after CMS induction at the sixth week
(n = 8 in both tests). Pioglitazone (2.5 mg/kg) reduced this increase. In the locomotor activity test, pioglitazone improved the spontaneous activity
level after CMS induction (h, n = 8). *p < 0.05, * *p < 0.01 vs. Control; #p < 0.05, ##p < 0.01 vs. CMS + Vehicle. Data are expressed as means ± SEM
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Fig. 2 The activity of PPARγ affected the improvement of depression-like behaviors. a The principle scheme of the experimental project. BW at
the baseline level (b) and the sixth week (c) (n = 10). SP showed no differences at week 0 (d). Pioglitazone improved the ratio of the SP in CMS
mice but anhedonia was maintained with the antagonist of PPARγ, GW9662, administration (e, n = 10). Spontaneous activity was modulated by
pioglitazone and GW9662 (f, n = 8). Pioglitazone decreased the time of immobility, but GW9662 increased the immobility duration in the FST and
TST (g, h, n = 8 in both tests). *p < 0.05, **p < 0.01 vs. Control; #p < 0.05, ##p < 0.01 vs. CMS + Vehicle; $$p < 0.01 vs. CMS + Piog. Data are expressed
as means ± SEM
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Fig. 3 Microglial activated status was influenced by PPARγ in the hippocampus. Pioglitazone decreased the number of Iba1+ microglia compared with
the CMS mice. The Iba1+ microglial morphology was amoeboid, and the number of microglia increased in the animals after GW9662 treatment.
Administration of pioglitazone and GW9662 had no effect on the microglia (b, n = 5). Enlarged figures indicate typical microglia (a). Scale bars: 10 μm.
**p < 0.01 vs. Control; ##p < 0.01 vs. CMS + Vehicle; $$p < 0.01 vs. CMS + Piog. Data are expressed as means ± SEM
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the control groups. Pioglitazone significantly in-
creased the levels of IkBα in the LPS-treated N9
cells, and GW9662 reversed this effect. Pioglitazone
markedly upregulated the protein levels of IkBα,
which repressed the inhibition of NF-kB activity
(Fig. 7k: p = 0.026).
Discussion
In this study, we investigated the antidepressant effect of
pioglitazone and explored its underlying anti-inflammatory
responses. First, pioglitazone ameliorated depression-like
behaviors in CMS-treated mice, but this amelioration was
diminished by GW9662. Second, pioglitazone exerted
Fig. 4 Effect of pioglitazone treatment on microglia-inhibited M1 activation in the DG of the hippocampus. The expression of M1 markers IL-1β (a), IL-
6 (b), TNFα (c), iNOS (d), and CCL2 (e) increased; pioglitazone reduced this increase and GW9662 aggravated this increase in the CMS mice. n = 5. *p <
0.05, **p < 0.01 vs. Control; #p < 0.05, ##p < 0.01 vs. CMS + Vehicle; $p < 0.05, $$p < 0.01 vs. CMS + Piog. Data are expressed as means ± SEM
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antidepressant effects through the anti-inflammatory activ-
ity of the PPARγ pathway. Third, pioglitazone improved
CMS-induced depression-like behavior by regulating which
of the microglial phenotypes (M1 or M2) was activated.
MDD is a common and sometimes fatal disorder that
has increasingly become a public health concern. Accu-
mulating evidence suggests that chronic low-grade in-
flammation plays an important role in the pathology of
depression. Over the past two decades, great effort has
been made to identify novel targets for antidepressant
therapies. It has been proposed that pioglitazone, work-
ing as an anti-inflammatory agent, could produce anti-
depressant responses in patients with concomitant
metabolic syndrome and diabetes [36, 37]. In our study,
we assessed the antidepressant efficacy of pioglitazone
on a CMS model, which is commonly used to induce
Fig. 5 Effect of pioglitazone treatment on the microglial shift toward an M2 phenotype. The mRNA expression of M2: Ym1 (a), Arg1 (b), IL-4 (c),
IL-10 (d), and TGFβ (e) reduced with a 6-week duration of CMS stress. The decreases were attenuated by pioglitazone administration. GW9662 still
reduced the expression of these markers. Pioglitazone and GW9662 treated together had no effect on the M2 level of CMS mice. n = 5. *p < 0.05,
**p < 0.01 vs. Control; #p < 0.05, ##p < 0.01 vs. CMS + Vehicle; $p < 0.05, $$p < 0.01 vs. CMS + Piog. Data are expressed as means ± SEM
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Fig. 6 LPS-induced M1 polarization was alleviated by the PPARγ agonist pioglitazone in N9 microglial cells. LPS increased the level of IL-1β (a), IL-
6 (b), TNFα (c), iNOS (d), and CCL2 (e), but this was reversed by pioglitazone. The PPARγ antagonist GW9662 inhibited the effect of pioglitazone
on the PPARγ of microglia. The protein expression of IL-1β (f) and TNFα (g) was detected by ELISA. *p < 0.05, **p < 0.01 vs. Control; #p < 0.05, ##p <
0.01. Data are expressed as means ± SEM
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Fig. 7 (See legend on next page.)
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and measure depression (Fig. 1). Because pioglitazone
can cross the blood brain barrier, intragastric injection
was selected for the CMS mice. Pioglitazone increased
the SP in CMS-induced depressant model, which was
blocked by the PPAR-γ antagonist GW9662. Pioglitazone
as well decreased the time of immobility in FST and TST
in the CMS-treated mice, indicating that pioglitazone has
a therapeutic action in CMS-induced depression-like be-
haviors. CMS induced a decrease in locomotor activity indi-
cated a depressive state of animals because of a loss of
interest for the movement, or for exploring the environ-
ment. Pioglitazone increased spontaneous motor activity in
the CMS-exposed mice, without effect on locomotor activ-
ity in normal mice [38]. Gavage administration of pioglita-
zone was effective at the 2.5 and 5.0 mg/kg doses for
ameliorating the symptoms of depression, but the
2.5 mg/kg dosage was more effective. Dosages of 10
and 20 mg/kg were not efficacious in the CMS mice.
As a result, the 2.5 mg/kg dose was chosen to treat
the CMS mice in the subsequent experiments.
PPARγ is a ligand-dependent transcription factor be-
longing to the nuclear hormone receptor superfamily
implicated in adipocyte differentiation, insulin sensitivity,
and inflammatory processes [39, 40]. PPARγ is constitu-
tively expressed in macrophages and CNS-resident micro-
glia, acting as a key regulator of microglial activation [41].
Activation of PPARγ signaling has a protective role by
reducing neuroinflammation [42], a finding which may
present a novel therapeutic approach for diseases, in-
cluding Alzheimer’s disease [20, 43], Parkinson’s disease
[24, 44], stroke [45], schizophrenia, and autism [22]. In
light of the anti-inflammatory and neuroprotective ac-
tivities of the PPARγ-dependent signaling pathway, we
investigated the antidepressant effects of pioglitazone in
a CMS mice model of depression. GW9662, a selective an-
tagonist for PPARγ, was administered in this investigation
in order to explore the possible role of PPARγ activation
on the antidepressant activities of pioglitazone (Fig. 2).
After treatment with GW9662, the BW loss was greater
than that in the CMS-treated mice. GW9662 significantly
inhibited the pioglitazone-induced reduction in the
duration of immobility in the FST and TST. GW9662
also counteracted the effect of pioglitazone on PPARγ
activation. These results suggest that pioglitazone ex-
erts antidepressant-like effects at least in part due to
the activation of the PPARγ pathway.
Microglia play a crucial role in inflammation modula-
tion in the CNS, and microglial dysfunction is believed
to result in CNS immune disorders [46, 47]. The role of
microglia has long been considered in some neurode-
generative diseases [48, 49]. Some interesting evidence
about this role in depression has also began to emerge
in recent years, e.g., microglial activation and the expres-
sion of inflammatory mediators have been reported in
an olfactory bulbectomised (OB) rat model of depression
[50]. According to in vitro research, microglia and their
polarization status play an essential role in depression
initiation [51]. These data indicated that the immune
system was activated in the stressed depression models.
This may have been due to the activation of M1 micro-
glia [35]. Here, we showed that the microglial cells had
large somas, short thick processes, and the amoeboid
morphology typical of activated microglia after CMS ini-
tiation (Fig. 3a). This morphology has been explained in
our previous experiments [12, 35]. Microglial activated
phenotypes were determined by their polarized markers.
We confirmed that the M1 markers (IL-1β, IL-6, TNFα,
iNOS, and CCL2) were induced and that the M2 mole-
cules (Ym1, Arg1, IL-4, IL-10, and TGFβ) were impaired
in depression. Pioglitazone restored the balance of the
M1 and M2 microglia in the hippocampus of the CMS
mice (Figs. 4 and 5). The hippocampus has been impli-
cated in the inhibition of stress responses [52] and in the
regulation of affective states and emotional behavior
[53]. Prior studies have shown that stress primed neu-
roinflammatory processes characterized by microglial
activation [14, 15]. Microglial activation plays a vital role
in the pathogenesis of many neurodegenerative diseases.
Experiments in animal models have provided more
direct evidence for a role of activated microglia in de-
pression [50, 54]. In our experiment, we found that
pioglitazone can control microglia activation and neuro-
inflammation in CMS-induced depression. These data in-
dicated that microglia-modulating agents had therapeutic
benefits for MDD, thereby defining a new biological
activity for pioglitazone by showing that pioglitazone acts
in modulating microglial phenotypes in a CMS-induced
rodent model of depression.
Inflammatory cytokines play a significant role in de-
pression. In our previous study, an imbalance between
the pro- and anti-inflammatory cytokines may be one of
the pathogeneses of depression [6]. In this current
(See figure on previous page.)
Fig. 7 The M2 molecules: Ym1 (a), Arg1 (b), IL-4 (c), IL-10 (d), and TGFβ (e) decreased with LPS treatment. Pioglitazone increased the expression
of the M2 markers. The impact on the LPS+Piog+GW group was similar to that of the LPS microglial cells. The level of Ym1 (f & g) and Arg1 (h &
i) was also confirmed by western blot. The protein expression of IκBα decreased in LPS-stimulated cells; pioglitazone significantly ameliorated the
expression. GW9662 suppressed the rise after pioglitazone-treated LPS in microglia (j & k).*p < 0.05, **p < 0.01 vs. Control; #p < 0.05, ##p < 0.01. Data
are expressed as means ± SEM
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research, a higher expression of IL-1β, IL-6, and TNFα,
and a lower expression of IL-4, IL-10, and TGF-β were
observed in the hippocampus of CMS-induced mice
(Figs. 4 and 5). A relatively large body of evidence has
suggested that the PPARγ agonist pioglitazone can
regulate the inflammatory response and oxidative stress
[55, 56]. After pioglitazone treatment of the CMS mice,
the expression of pro-inflammatory molecules was
reduced and the levels of anti-inflammatory cytokines
were increased. These results were consistent with re-
cent findings that PPARγ agonists can transition M1 into
M2 phenotype as well as enhance the production of
anti-inflammatory cytokines such as IL-10 and TGFβ,
both of which are pro-neurogenic [57, 58]. In order to
ensure the specific response of activated microglia in
stress-induced depression, experiments using LPS treat-
ment of N9 microglial cells were performed. LPS can
cause behavioral changes that indicate depression [59].
LPS stimulation can break the balance of microglial acti-
vation (M1 vs. M2), but the resulting imbalance in the
levels of mRNA and protein can be ameliorated by pioglit-
azone administration (Fig. 6 and Fig. 7a–i). The results of
an in vitro study were consistent with the mice test. Thus,
the M1-M2 imbalance should be a focus in studying ani-
mal models of depression [50]. NF-kB pathway activation
plays an important role in pro-inflammatory gene expres-
sion after stimulation [60, 61]. NF-kB normally exists in
the cytoplasm, binding to its inhibitory proteins (IkB) and
remaining inactive. Dissociation of IkB induces activation
of NF-kB and facilitates the transcription of inflammatory
genes [62]. In our experiment, the protein expression of
IkB was reduced after an LPS stimulation of N9 microglial
cells. Pioglitazone upregulated the IkBα expression in the
LPS-treated N9 cells and GW9662 reversed the inhibitory
effects of pioglitazone on NF-kB activity (Fig. 7k). These
results indicated that the role of pioglitazone in preventing
the NF-kB activation was partially linked to the upregula-
tion of IkB expression. The present findings suggest that
the anti-inflammatory effects of pioglitazone are associ-
ated with a PPARγ-mediated suppression of the NF-kB
signaling pathway with consequential inflammatory cyto-
kine expression in microglial cells.
Conclusions
In summary, the present study demonstrated for the first
time that the chronic administration of pioglitazone
induced the neuroprotective phenotype of microglia in
parallel with the amelioration of depression-like behaviors
in CMS-treated C57BL/6 mice. Pioglitazone, a microglia-
modulating drug which regulates anti-inflammatory activ-
ity, may partially account for the observed antidepressant
response. This finding suggests that targeting microglia
could pave the way for new depression treatments.
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